RecruitingNCT06349252

Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer

Sponsor

Fudan University

Enrollment

1,263 participants

Start Date

Jan 1, 2021

Study Type

OBSERVATIONAL

Conditions

Non-small Cell Lung Cancer

Summary

The International Association for the Study of Lung Cancer Staging Committee recently unveiled the ninth edition of TNM staging system for lung cancer. This study aims to explore survival outcomes, stage grouping, and gene mutations in N descriptors of this new classification system.

Eligibility

Plain Language Summary

Simplified for easier understanding

This observational study collects data from people with lung cancer to validate how the spread to nearby lymph nodes (called N2 disease) affects survival, as part of updating international cancer staging guidelines. **You may be eligible if...** - You have been found to have lung cancer with spread to mediastinal lymph nodes (classified as pathological N2 stage) - Your diagnosis was confirmed through surgical pathology **You may NOT be eligible if...** - You received chemotherapy before your surgery (neoadjuvant chemotherapy) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.